Epigenetic alterations in intraductal papillary mucinous neoplasms of the pancreas
Authors:
- 26 July 2006
- journal article
- review article
- Published by Springer Nature in Journal of Hepato-Biliary-Pancreatic Surgery
- Vol. 13 (4) , 280-285
Abstract
Intraductal papillary mucinous neoplasm (IPMN), an increasingly recognized cystic neoplasm of the pancreas with a broad spectrum of malignant potential, has been considered a precursor to infiltrating ductal adenocarcinoma. Because of its unique clinical, radiological, pathological, and molecular features, IPMN has attracted considerable interest among clinicians and researchers. Although some genetic alterations have been described in IPMNs, the molecular features that characterize the evolution and progression of these neoplasms are largely unknown. Recent studies have shown that aberrant methylation of the promoter cytosine-phospho-guanine (CpG) island is a common mechanism associated with the silencing of tumor-suppressor and cancer-related genes in IPMNs. Importantly, the prevalence of such methylation increases along with the grade of neoplasia, suggesting that these epigenetic events may contribute to the progression of IPMNs. Further studies of epigenetic alterations in IPMN will shed light on the molecular pathogenesis of this unique neoplasm and lead to the identification of epigenetic markers that can be applied in the clinical setting.Keywords
This publication has 56 references indexed in Scilit:
- Clinical aspects of intraductal papillary mucinous neoplasm of the pancreasJournal of Gastroenterology, 2005
- Molecular Markers of Early Pancreatic CancerJournal of Clinical Oncology, 2005
- Multicenter Analysis of Clinicopathologic Features of Intraductal Papillary Mucinous Tumor of the Pancreas: Is It Possible to Predict the Malignancy Before Surgery?Annals of Surgical Oncology, 2005
- Intraductal Papillary Mucinous Neoplasms of the PancreasAnnals of Surgery, 2004
- Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profilingOncogene, 2003
- SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactionsOncogene, 2003
- The power and the promise of DNA methylation markersNature Reviews Cancer, 2003
- Exclusion of SMAD4 mutation as an early genetic change in human pancreatic ductal tumorigenesisGenes, Chromosomes and Cancer, 2001
- Intraductal papillary mucinous tumours of the pancreas. Clinical and therapeutic issues in 32 patients.Gut, 1996
- Intraductal papillary-mucinous tumors of the pancreas: Clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of Mayo ClinicGastroenterology, 1996